The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Updates from ADAURA: continued DFS benefit with osimertinib vs. placebo
Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, presents updated results from ADAURA (NCT02511106), a Phase III trial evaluating osimertinib, a third generation EGFR tyrosine kinase inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). With 2-years further follow-up, a continued disease-free survival (DFS) benefit was observed in the experimental arm which is consistent with the primary analysis and supports the use of osimertinib as standard of care for patients with EGFR-mutant stage IIB-IIIA NSCLC after complete tumor resection and adjuvant chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
